GTx GTXI
-
Thursday's Bio-Pharma Drug Approval And Catalyst Event List
By Scott Matusow : Catalyst trades in the bio pharma sector can provide big profits if traded correctly. Some traders and investors who enjoy bringing more risk into play often times will hold through the catalyst event. While this does bring a lot more risk into play, the reward from engaging in
-
12 Healthcare Companies Expecting May Catalysts
By Spencer Knight : As a rocky month of April comes to a close, the month of May looks to be very exciting for the Healthcare and Biotech sectors. There are 14 events scheduled for May, including a few very high profile treatments. Healthcare and particularly biotech trading can be very lucrative
-
As integrated processors from Intel and AMD increasingly threaten its low-end graphics processor sales, Nvidia (NVDA) is boosting its efforts to cater to high-end enthusiasts. The latest example is ...
… processor sales, Nvidia ( NVDA ) is boosting its efforts to cater to high-end enthusiasts. The latest example is the GeForce GTX 690 card: featuring 2 processors based on Nvidia's 28nm Kepler architecture, the 690 is expected to retail for $999, easily …
-
Wednesday, April 18th Bio-Pharma Mover Watch List
By Scott Matusow : I believe the following stocks could be on the upside move, today, Wednesday April 18th, 2012, which could make for a nice short term gain for those who prefer short term swing trading. Achillion ( ACHN) Achillion will be releasing results of its Phase IIa clinical trials of ...
-
ArQule Dips, But Not Necessarily A Bargain
By Stephen Simpson : There are really only two reliable catalysts for biotech stocks - reporting clinical data and announcing equity offerings - and the latter one is seldom a positive for the stock. With ArQule ( ARQL ) looking to increase its sharecount by more than 11% (including the shoe), ...
-
Bio-Pharma Catalyst Trades That Offer Decent Short-Term Gains
… long term multi-bagger opportunity. GTX ( GTXI ) engages in the discovery, development ..... castrates prostate cancer patients. GTX discovered larger dosages of the drug ..... continue. The FDA will decide whether GTX has demonstrated Complete Story »
-
Analyzing GTx , Inc.'s Vast Upside Potential
… stocks that get too expensive. In GTx Inc. ( GTXI ), a developer of a new class of cancer ..... two very compelling reasons to buy GTXI on this recent dip. These include recent bullish analyst comments on GTXI 's Complete Story »
-
Nvidia (NVDA) has rolled out its high-end GTX 680 graphics processor ((GPU)), the first chip based on its delayed "Kepler" architecture, which uses a 28nm manufacturing process from TSMC (TSM). The ...
Nvidia ( NVDA ) has rolled out its high-end GTX 680 graphics processor (GPU), the first chip based on its ..... first 28nm GPU . Nonetheless, AnandTech is impressed with the GTX 680, declaring Nvidia to have regained the performance crown …
-
Early Innovations In The Breast Cancer Therapeutic Market
By Andrew J. Norris : Breast cancer is the most commonly diagnosed malignancy and one of the major causes of death among women. It is also one of the most investigated diseases, but its biological features are still not well understood. The number of breast cancer cases in US in 2011 include ...
-
Premarket gainers: [[CORT]] +61%. [[THLD]] +59%. [[PBH]] +24%. [[CTIC]] +11%. [[CHG]] +10%. [[STM]] +8%. [[SWC]] +8%. [[JASO]] +7%. [[WYNN]] +6%. [[IVAN]] +6%. [[SSN]] +5%. [[YGE]] +5%. [[HL]] +4%. ...
… HL +4% . IRE +4% . TSL +4% . FRO +3% . M +3% . HD +3% . DANG +3% . CS +3% . STP +3% . NG +3% . Losers: GTXI -39% . CHTP -13% . WFT -11% . CTRP -9% . CIE -5% . NBG -5% . RIG -5% . CIEN -4% . WMT -3% . Post your comment …